Table 2 Estimated changes per month in lipid levels, insulin resistance and Framingham risk score
Variable | Increase per month Regression coefficient (95% CI)# | Increase per month2 Regression coefficient (95% CI)# | p |
|---|---|---|---|
Total-C (mmol/L) | |||
Stavudine | 0.1275 (0.1035–0.1514) | − 0.0037 (− 0.0047 to − 0.0027) | |
Tenofovir | 0.0719 (0.0621–0.0818) | − 0.0020 (− 0.0025 to − 0.0016) | < 0.001 |
HDL-C (mmol/L) | |||
Stavudine | 0.0721 (0.0572–0.0870) | − 0.0024 (− 0.0031 to − 0.0018) | |
Tenofovir | 0.0433 (0.0372–0.0495) | − 0.0012 (− 0.0014 to − 0.0009) | < 0.001 |
LDL-C (mmol/L) | |||
Stavudine | 0.0516 (0.0324–0.0709) | − 0.0013 (− 0.0021 to − 0.0005) | |
Tenofovir | 0.0254 (0.0175–0.0334) | − 0.0007 (− 0.0010 to − 0.0004) | 0.036 |
Log TG (mmol/L) | |||
Stavudine | 0.0125 (− 0.0017–0.0268) | − 0.0001 (− 0.0007–0.0005) | |
Tenofovir | 0.0073 (0.0014–0.0132) | − 0.0003 (− 0.0006 to − 0.0001) | 0.058 |
Glucose (mmol/L) | |||
Stavudine | 0.0689 (0.0393–0.0980) | − 0.0021 (− 0.0033 to − 0.0009) | |
Tenofovir | 0.0679 (0.0558–0.0800) | − 0.0020 (− 0.0026 to − 0.0015) | 0.991 |
Insulin (pmol/L) | |||
Stavudine | 0.3941 (− 1.3102–2.0984) | 0.0045 (− 0.0659–0.0749) | |
Tenofovir | 0.0042 (− 0.7001–0.7086) | 0.0231 (− 0.0059–0.0521) | 0.677 |
Log HOMA-IR | |||
Stavudine | 0.0242 (0.0006–0.0479) | − 0.0004 (− 0.0014–0.0006) | |
Tenofovir | 0.0158 (0.0060–0.0255) | − 0.0002 (− 0.0006–0.0003) | 0.756 |
Logit Framingham risk score* | |||
Stavudine | 0.0100 (− 0.0050–0.0251) | − 0.0001 (− 0.0008–0.0005) | |
Tenofovir | − 0.0047 (− 0.0109–0.0016) | 0.0002 (0.0000–0.0005) | 0.144 |